{"url_path":"/sec/aidx/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1139685/0001213900-26-059542-index.html","accession_number":"0001213900-26-059542","cik":"0001139685","ticker":"AIDX","issuer_name":"20/20 Biolabs, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1139685/0001213900-26-059542-index.html","primary_entity_key":"0001139685","primary_entity_name":"20/20 Biolabs, Inc."},"word_count":533,"has_tables":true,"body_markdown":"**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n** **\n\n(Mark One)\n\n**☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nFor the quarterly period ended: March 31, 2026\n\n \n\nor\n\n \n\n**☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nFor the transition period from ____________ to\n_____________\n\n \n\nCommission File Number: 001-43128\n\n \n\n**20/20 BIOLABS, INC.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Delaware**   **57-2272107**\n\n(State or other jurisdiction of\nincorporation or organization)   (I.R.S. Employer\nIdentification No.)\n\n     \n\n**15810 Gaither Road, Suite 235, Gaithersburg, MD**   **20877**\n\n(Address of principal executive offices)   (Zip Code)\n\n \n\n**240-453-6339**\n\n(Registrant’s telephone number, including area code)\n\n \n\n**N/A**\n\n(Former name, former address and former fiscal year, if changed since last report)\n\n \n\nSecurities registered pursuant to Section 12(b)\nof the Act:\n\n \n\n**Title of each class**   **Trading Symbol(s)**   **Name of each exchange on which registered**\n\nCommon Stock, par value $0.01   AIDX   The Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant\n(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months\n(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements\nfor the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant\nhas submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding\n12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒\nNo ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated\nfiler, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions\nof “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging\ngrowth company” in Rule 12b-2 of the Exchange Act.\n\n \n\n  Large accelerated filer ☐   Accelerated filer ☐\n\n  Non-accelerated filer ☒   Smaller reporting company ☒\n\n      Emerging growth company ☒\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nAs\nof May 19, 2026, there were 10,611,528 shares of common stock of the registrant issued and outstanding.\n\n \n\n \n\n \n\n \n\n \n\n**20/20 Biolabs, Inc.**\n\n** **\n\n**Quarterly Report on Form 10-Q**\n\n**Period Ended March 31, 2026**\n\n \n\n** **\n\n**TABLE OF CONTENTS**\n\n** **\n\n \n\n** **\n**PART I\nFINANCIAL INFORMATION**\n** **\n\n \n \n \n\n[Item 1.](#k_002)\n[Financial Statements](#k_002)\n1\n\n[Item 2.](#k_008)\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#k_008)\n2\n\n[Item 3.](#k_009)\n[Quantitative and Qualitative Disclosures About Market Risk](#k_009)\n9\n\n[Item 4.](#k_010)\n[Controls and Procedures](#k_010)\n9\n\n \n \n \n\n** **\n**PART II\nOTHER INFORMATION**\n\n** **\n\n[Item 1.](#k_012)\n[Legal Proceedings](#k_012)\n10\n\n[Item 1A.](#k_013)\n[Risk Factors](#k_013)\n10\n\n[Item 2.](#k_014)\n[Unregistered Sales of Equity Securities and Use of Proceeds](#k_014)\n10\n\n[Item 3.](#k_015)\n[Defaults Upon Senior Securities](#k_015)\n10\n\n[Item 4.](#k_016)\n[Mine Safety Disclosures](#k_016)\n10\n\n[Item 5.](#k_017)\n[Other Information](#k_017)\n10\n\n[Item 6.](#k_018)\n[Exhibits](#k_018)\n11\n\n \n\ni\n\n \n\nPART I\n\nFINANCIAL INFORMATION"}